Supplementary

Appendix 1

Case Report Form (CRF)

Site _____ Department _____ Investigator _____

1. **Subject information**
   - Initial:
   - Date of birth:
   - Gender:
   - Diagnosis:
   - Surgery (☐Emergency ☐Regular):
   - Surgery date (Date of SurgiGuard® Use):
   - Comorbidity: ☐Hypertension ☐Diabetes ☐Liver disease ☐Renal disease ☐other
   - Concomitant drug ☐Antihypertensive ☐Hypoglycemic agent ☐Liver disorder ☐Anticoagulant ☐Hormone ☐Immunosuppressant ☐other

2. **Usage of SurgiGuard®**

2.1 SurgiGuard® Product name

☐ SurgiGuard® Original	☐5 cm x 7.5 cm (2inch x 3inch) ☐5 cm x 35 cm (2inch x 14inch) ☐10 cm x 20 cm (4inch x 8inch) ☐1.25 cm x 5 cm (0.5inch x 2inch)
☐ SurgiGuard® Fabric	☐5 cm x 7.5 cm (2inch x 3inch) ☐7.5 cm x 10 cm (3inch x 4inch) ☐15.2 cm x 22.9 cm (6inch x 9inch) ☐2.5 cm x 2.5 cm (1inch x 1inch) ☐2.5 cm x 7.5 cm (1inch x 3inch)
☐ SurgiGuard® Fibrillar	☐2.5 cm x 5.1 cm (1inch x 2inch) ☐5.1 cm x 10.2 cm (2inch x 4inch) ☐10.2 cm x 10.2 cm (4inch x 4inch)
☐ SurgiGuard® Non-woven	☐2.5 cm x 5.1 cm (1inch x 2inch) ☐5.1 cm x 10.2 cm (2inch x 4inch) ☐10.2 cm x 10.2 cm (4inch x 4inch)

2.2 Number of SurgiGuard® used in surgery

☐ 1
☐ 2
☐ 3

© Gland Surgery. All rights reserved.
https://dx.doi.org/10.21037/gs-22-675

☐ 4

☐ More than 5

2.3 Whether you use SurgiGuard® alone or in combination with other products?(When using combination, please select a duplicate)

☐ SURGIGUARD (ORC)

☐ SURGICEL (ORC)

☐ EVICEL (Fibrin)

☐ TACHOSIL (Fibrin)

☐ TISSEEL (Fibrin)

☐ GREENPLAST (Fibrin)

☐ BERIPLAST (Fibrin)

☐ FLOSEAL (Fibrin)

☐ COSEAL (Synthetic Sealant)

☐ DURASEAL (Synthetic Sealant)

☐ BIOGLUE (Albumin Sealant)

☐ AVITENE (Collagen)

☐ COLLAPAD (Collagen)

☐ BLEESTOP (Collagen)

☐ other ( )

2.4 Removal of SurgiGard® after hemostasis

☐ Removed

☐ Not removed

☐ other ( )

3. SurgiGard® Hemostatic effect

3.1 Hemostasis effect of SurgiGuard® as hemostasis supplement(6 point scale)

: _____._____ points (Please, display the first decimal place)

Extremely satisfied (6)	Very satisfied (5)	Somewhat satisfied (4)	Somewhat dissatisfied (3)	Very dissatisfied (2)	Extremely dissatisfied (1)

3.2 User Satisfaction with SurgiGuard® Surgical Handling as hemostasis supplement

Extremely satisfied (6)	Very satisfied (5)	Somewhat satisfied (4)	Somewhat dissatisfied (3)	Very dissatisfied (2)	Extremely dissatisfied (1)

3.3 If there was no hemostatic effects (1-2 point), why?

☐ Comorbidity (Liver disease, Renal disease, Sepsis, etc)

© Gland Surgery. All rights reserved.
https://dx.doi.org/10.21037/gs-22-675

☐ Extensive bleeding
☐ Vascular injury
☐ Concomitant drug (Aspirin, Wafarin, Platelet aggregation inhibtor, etc)
☐ Lack of SurgiGuard® usage (Use less than the right amount or the right size)
☐ other ( )

4. Operative characteristics

- Intraoperative blood loss (ml):_____ml
- Intraoperative blood transfusion: ☐ Yes ☐ No
- Pre/Post-operative hemoglobin level

  ① Pre-operative Hemoglobin:_____

  ② Post-operative day-1 Hemoglobin:_____
- Postoperative drain tube insertion: ☐ Yes ☐ No

  ① If yes, drainage volume within 1 day after operation:_____ml
- Re-bleeding after using SurgiGuard®: ☐ Yes ☐ No

  ① If there **was no re-bleeding**, the time until the complete hemostasis was confirmed after the surge guard was applied: ( ) min

  ② If there **was re-bleeding**, the time from to re-bleeding after SurgiGuard® application: ( ) min

  ③ Treatment for re-bleeding: **(When using the combination, please select a duplicate)**

  ☐ SURGIGUARD (ORC)
  ☐ SURGICEL (ORC)
  ☐ EVICEL (Fibrin)
  ☐ TACHOSIL (Fibrin)
  ☐ TISSEEL (Fibrin)
  ☐ GREENPLAST (Fibrin)
  ☐ BERIPLAST (Fibrin)
  ☐ FLOSEAL (Fibrin)
  ☐ COSEAL (Synthetic Sealant)
  ☐ DURASEAL (Synthetic Sealant)
  ☐ BIOGLUE (Albumin Sealant)
  ☐ AVITENE (Collagen)
  ☐ COLLAPAD (Collagen)
  ☐ BLEESTOP (Collagen)
  ☐ other ( )

  ④ Reoperation due to bleeding after the operation: ☐ Yes ☐ No

5. Adverse events after using SurgiGuard® (Side effects)

5.1 Adverse events occurred within 24 hours after surgery

☐ Yes ☐ No

5.2 If there was an adverse events

☐ Requiring transfusion blood products
☐ Bleeding/leakage from treated site

© Gland Surgery. All rights reserved.
https://dx.doi.org/10.21037/gs-22-675

☐ Hemorrhage
☐ Allergic Reaction
☐ Abscess
☐ Granuloma
☐ Obstruction
☐ Stroke
☐ Ischemia
☐ Sepsis
☐ Infection
☐ Deep Vein Thrombosis
☐ Cellulitis
☐ Ischemia
☐ Pericardial Effusion
☐ Respiratory dysfunction
☐ other ( )

5.3 Relationship between Adverse Events and SurgiGard®

☐ Related ☐ Not related ☐ Not evaluable

© Gland Surgery. All rights reserved.
https://dx.doi.org/10.21037/gs-22-675